Experience with aflibercept as a second line chemotherapy in metastatic colorectal cancer:
Safety and efficacy in a real-life po Page 1 of Epidemiology and Biostatistics, University of Tokyo …

Background The objectives of this study were to evaluate the safety profile of aflibercept and
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …

Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …

Objective: Aflibercept increased overall survival with acceptable tolerability in metastatic
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …

Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …

Methods: Data from VELOUR were analyzed by the Kaplan-Meier method to determine
median OS from first day of 1L treatment until death in prespecified subgroups according to …

Background Although no data have been reported beyond second-line therapy, aflibercept
is approved in this setting in many countries. We conducted a multicenter study to analyze …

Introduction Aflibercept is a recombinant human fusion protein that acts as a decoy receptor
preventing VEGF-A, VEGF-B, and PlGF from interacting with their receptors. The phase 3 …

Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in
the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study …

Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular
endothelial growth factor (VEGF), a key regulator of angiogenesis. It binds to all isoforms of …